Search

Your search keyword '"Bartolomeo, Paolo Di"' showing total 15 results
Start Over Author "Bartolomeo, Paolo Di"
15 results on '"Bartolomeo, Paolo Di"'

1. Regione Veneto - Gestione della rete di controllo sismico, studio della sismicita regionale e ricerca ' sismologica a fini di protezione civile Anno 2019

Author

Bragato, Pier Luigi, Sugan, Monica, Snidarcig, Adriano, Urban, Sandro, Barnaba, Carla, Bernardi, Paolo, Bertoni, Michele, Bressan, Gianni, Comelli, Paolo, Negro, Elvio Del, Dreossi, Ilaria, Bartolomeo, Paolo Di, Fabris, Paolo, Gentili, Stefania, Laurenzano, Giovanna, Magrin, Andrea, Moratto, Luca, Palmieri, Francesco, Peresan, Antonella, Peruzza, Laura, Pesaresi, Damiano, Linares, Milton P. Plasencia, Poggi, Valerio, Ponton, Cristian, Priolo, Enrico, Rebez, Alessandro, Restivo, Andrea, Romanelli, Marco, Romano, Maria Adelaide, Scaini, Chiara, Saraò, Angela, Sandron, Denis, Vuan, Alessandro, and Zuliani, David

Published
2020
Full Text
View/download PDF

4. Regione Veneto - Gestione della rete di controllo sismico, studio della sismicita' regionale e ricerca sismologica a fini di protezione civile Anno 2018

Author

Bragato, Pier Luigi, Sugan, Monica, Snidarcig, Adriano, Urban, Sandro, Barnaba, Carla, Bernardi, Paolo, Bertoni, Michele, Bressan, Gianni, Comelli, Paolo, Negro, Elvio Del, Dreossi, Ilaria, Bartolomeo, Paolo Di, Fabris, Paolo, Gentili, Stefania, Laurenzano, Giovanna, Magrin, Andrea, Moratto, Luca, Palmieri, Francesco, Peresan, Antonella, Peruzza, Laura, Pesaresi, Damiano, Linares, Milton P. Plasencia, Ponton, Cristian, Priolo, Enrico, Rebez, Alessandro, Restivo, Andrea, Romanelli, Marco, Romano, Maria Adelaide, Saraò, Angela, Sandron, Denis, Vuan, Alessandro, and Zuliani, David

Published
2019
Full Text
View/download PDF

5. Family mismatched allogeneic stem cell transplantation for Myelofibrosis: Report from the Chronic Malignancies Working Party of EBMT

Author

Raj, Kavita, Eikema, Diderik-Jan, McLornan, Donal P, Olavarria, Eduardo, Blok, Henric-Jan, Bregante, Stefania, Ciceri, Fabio, Passweg, Jakob, Ljungman, Per, Schaap, Nicolaas, Carlson, Kristina, Zuckerman, Tsila, de Wreede, Liesbeth C, Volin, Liisa, Koc, Yener, Diez-Martin, J, Brossart, Peter, Wolf, Dominik, Blaise, Didier, Bartolomeo, Paolo Di, Vitek, Antonin, Robineau, Marie, Yakoub-Agha, Ibrahim, Chalandon, Yves, and Kroger, Nicolaus

Subjects
ddc:616
Abstract

This analysis includes 56 Myelofibrosis (MF) patients transplanted from family mismatched donor between 2009-2015 enrolled in the European Society for Blood and Marrow Transplantation (EBMT) database. The median age was 57 years (range, 38-72); 75% had primary MF and 25% had secondary MF. JAK2 V617F was mutated in 61%. Donors were HLA mismatched at 2 or more loci. Stem cells were sourced from bone marrow in 66% and peripheral blood in 34%. The median CD34+ cell dose was 4.8 × 106/kg (1.7-22.9 × 106/kg) (n=43). Conditioning was predominantly myeloablative (MAC) in 70% and reduced intensity (RIC) in the remainder. Regimens were heterogeneous with Thiotepa, Busulphan Fludarabine (TBF) and post-transplant cyclophosphamide (PTCy) used in 59%. The incidence of neutrophil engraftment by 28 days was 82% (range, 70-93%), at a median of 21 days (range,19-23). At 2 yrs. the CI of primary Graft failure was 9% (1-16%) and secondary graft failure was 13% (4-22%).The cumulative incidence (CI) of grades II-IV acute GvHD (aGvHD) and III-IV was 28% (16-40%) and 9% (2-17%) at 100 days. The CI of chronic GvHD (cGvHD) at 1 year was 45% (32-58%) but CI of death without cGVHD by 1 year was 20% (10-31%). With a median follow up of 32 months, the 1- and 2-year OS was 61% (48-74%) and 56% (41-70%) respectively. The 1- and 2- year PFS was 58% (45-71%) and 43% (28-58%) with a 2-year CI of relapse of 19% (7-31%). The 2-year non-relapse mortality (NRM) was 38% (24-51%). This retrospective study of MF allo-SCT utilising family mismatched donors, demonstrates feasibility of the approach, timely neutrophil engraftment in over 80% of cases and acceptable OS and PFS rates with relapse rates not dissimilar to the unrelated donor setting. However, strategies to minimise the risk of graft failure and the relatively high NRM need to be employed, ideally in a multicentre prospective fashion.

Published
2018

6. Family Mismatched Allogeneic Stem Cell Transplantation for Myelofibrosis: Report from the Chronic Malignancies Working Party of European Society for Blood and Marrow Transplantation

Author

Raj, Kavita, primary, Eikema, Diderik-Jan, additional, McLornan, Donal P, additional, Olavarria, Eduardo, additional, Blok, Henric-Jan, additional, Bregante, Stefania, additional, Ciceri, Fabio, additional, Passweg, Jakob, additional, Ljungman, Per, additional, Schaap, Nicolaas, additional, Carlson, Kristina, additional, Zuckerman, Tsila, additional, de Wreede, Liesbeth C., additional, Volin, Liisa, additional, Koc, Yener, additional, Diez-Martin, Jose Luis, additional, Brossart, Peter, additional, Wolf, Dominik, additional, Blaise, Didier, additional, Bartolomeo, Paolo Di, additional, Vitek, Antonin, additional, Robin, Marie, additional, Yakoub-Agha, Ibrahim, additional, Chalandon, Yves, additional, and Kroger, Nicolaus, additional

Published
2019
Full Text
View/download PDF

7. Regione Veneto - Gestione della rete di controllo sismico, studio della sismicita' regionale e ricerca sismologica a fini di protezione civile Anno 2017

Author

Bragato, Pier Luigi, Sugan, Monica, Snidarcig, Adriano, Urban, Sandro, Barnaba, Carla, Bernardi, Paolo, Bertoni, Michele, Bressan, Gianni, Comelli, Paolo, Negro, Elvio Del, Dreossi, Ilaria, Durì, Giorgio, Bartolomeo, Paolo Di, Fabris, Paolo, Gentili, Stefania, Moratto, Luca, Palmieri, Francesco, Peresan, Antonella, Peruzza, Laura, Pesaresi, Damiano, Linares, Milton P. Plasencia, Ponton, Cristian, Priolo, Enrico, Rebez, Alessandro, Restivo, Andrea, Romanelli, Marco, Romano, Maria Adelaide, Saraò, Angela, Sandron, Denis, Vuan, Alessandro, and Zuliani, David

Published
2017
Full Text
View/download PDF

8. Accordo tra la Regione Autonoma Friuli Venezia Giulia e l'OGS per la collaborazione nell'ambito del monitoraggio sismico e meteomarino Relazione 2016 -Ambito Sismologico

Author

Snidarcig, Adriano, Bragato, Pier Luigi, Barnaba, Carla, Bressan, Gianni, Comelli, Paolo, Durì, Giorgio, Fabris, Paolo, Gentili, Stefania, Moratto, Luca, Peresan, Antonella, Peruzza, Laura, Rebez, Alessandro, Rossi, Giuliana, Sandron, Denis, Saraò, Angela, Sugan, Monica, Urban, Sandro, Zuliani, David, Bernardi, Paolo, Bertoni, Michele, Negro, Del, Bartolomeo, Paolo Di, Grossi, Maurizio, Pesaresi, Damiano, Pettenati, Franco, Plasencia, Milton, Ponton, Cristian, Restivo, Andrea, and Romanelli, Marco

Published
2017
Full Text
View/download PDF

9. A National Retrospective Analysis of Data from the Italian Association of Pediatric Hematology Oncology (AIEOP)

Author

Messina, Chiara, Zecca, Marco, Fagioli, Franca, Rovelli, Attilio, Lanino, Edoardo, Bertaina, Alice, Fulvio, Porta, Aricò, Maurizio, Sieni, Elena, Ripaldi, Mimmo, Favre, Claudio, Pillon, Marta, Rabusin, Marco, Cesaro, Simone, Caniglia, Maurizio, Bartolomeo, Paolo Di, Ziino, Ottavio, Saglio, Francesco, Prete, Arcangelo, and Locatelli, Franco

Subjects
stem cell transplant, lymphohystyocytosis, lymphohystyocytosis, stem cell transplant
Published
2015

13. Unmanipulated, G-CSF-Primed Bone Marrow Transplantation From Haploidentical Donor for Patients with High-Risk Acute Myeloid Leukemia.

Author

Arcese, William, primary, Cerretti, Raffaella, additional, Santarone, Stella, additional, De Angelis, Gottardo, additional, Bavaro, Pasqua, additional, Testi, Manuela, additional, Cudillo, Laura, additional, Picardi, Alessandra, additional, Pennese, Elsa, additional, Papalinetti, Gabriele, additional, Dentamaro, Teresa, additional, Ceresoli, Eleonora, additional, Mariotti, Benedetta, additional, Piazza, Fabio Di, additional, and Bartolomeo, Paolo Di, additional

Published
2012
Full Text
View/download PDF

14. Cytogenetics Abnormalities Predict the Outcome of Allogeneic Transplantation In AML: A CIBMTR Study

Author

Armand, Philippe, primary, Perez, Waleska, additional, Zhang, Mei-Jie, additional, Kim, Haesook, additional, Klumpp, Thomas R., additional, Cin, Paola Dal, additional, Waller, Edmund K, additional, Litzow, Mark R., additional, Liesveld, Jane L., additional, Lazarus, Hillard M., additional, Artz, Andrew, additional, Gupta, Vikas, additional, Savani, Bipin N., additional, McCarthy, Philip L., additional, Cahn, Jean-Yves, additional, Schouten, Harry, additional, Finke, Jurgen, additional, Ball, Edward D., additional, Aljurf, Mahmoud, additional, Cutler, Corey, additional, Rowe, Jacob M., additional, Antin, Joseph H., additional, Isola, Luis M, additional, Bartolomeo, Paolo Di, additional, Camitta, Bruce, additional, Miller, Alan M, additional, Cairo, Mitchell S., additional, Stockerl-Goldstein, Keith E., additional, Sierra, Jorge, additional, Savoie, Mary Lynn, additional, Halter, Joerg, additional, Stiff, Patrick J, additional, Nabhan, Chadi, additional, Jakubowski, Ann A., additional, Bunjes, Donald, additional, Petersdorf, Effie W., additional, Devine, Steven M, additional, Maziarz, Richard, additional, Bornhauser, Martin, additional, Lewis, Victor A, additional, Marks, David I., additional, Bredeson, Christopher N, additional, Soiffer, Robert, additional, and Weisdorf, Daniel J., additional

Published
2010
Full Text
View/download PDF

15. Family Mismatched Allogeneic Stem Cell Transplantation for Myelofibrosis: Report from the Chronic Malignancies Working Party of European Society for Blood and Marrow Transplantation

Author

Paolo Bartolomeo, Tsila Zuckerman, Liisa Volin, Peter Brossart, Yener Koc, Donal P. McLornan, Jakob Passweg, Per Ljungman, Nicolaus Kröger, Dominik Wolf, Liesbeth C. de Wreede, Fabio Ciceri, Stefania Bregante, Kavita Raj, Kristina Carlson, Ibrahim Yakoub-Agha, Didier Blaise, Antonin Vitek, Eduardo Olavarria, Henric Jan Blok, José Luis Díez-Martín, Marie Robin, Nicolaas Schaap, Yves Chalandon, Diderik Jan Eikema, Raj, Kavita, Eikema, Diderik-Jan, Mclornan, Donal P, Olavarria, Eduardo, Blok, Henric-Jan, Bregante, Stefania, Ciceri, Fabio, Passweg, Jakob, Ljungman, Per, Schaap, Nicolaa, Carlson, Kristina, Zuckerman, Tsila, de Wreede, Liesbeth C., Volin, Liisa, Koc, Yener, Diez-Martin, Jose Lui, Brossart, Peter, Wolf, Dominik, Blaise, Didier, Bartolomeo, Paolo Di, Vitek, Antonin, Robin, Marie, Yakoub-Agha, Ibrahim, Chalandon, Yve, Kroger, Nicolaus, Clinicum, Department of Oncology, and HUS Comprehensive Cancer Center

Subjects
Male, Transplantation Conditioning, Databases, Factual, Cancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2], Graft vs Host Disease, Myelofibrosis, Gastroenterology, HEMATOLOGIC MALIGNANCIES, 0302 clinical medicine, Recurrence, CYCLOPHOSPHAMIDE, Cumulative incidence, Societies, Medical, Bone Marrow Transplantation, Incidence (epidemiology), Graft Survival, Hematopoietic Stem Cell Transplantation, Myelofibrosi, Hematology, Middle Aged, Mismatched related donor, 3. Good health, Fludarabine, Europe, 030220 oncology & carcinogenesis, Histocompatibility, Female, medicine.drug, Adult, medicine.medical_specialty, 3122 Cancers, ThioTEPA, POLYCYTHEMIA-VERA, Haploidentical, 03 medical and health sciences, Internal medicine, medicine, Humans, Transplantation, Homologous, Family, Aged, Retrospective Studies, Peripheral Blood Stem Cell Transplantation, Transplantation, Neutrophil Engraftment, business.industry, medicine.disease, Survival Analysis, ENGRAFTMENT, Primary Myelofibrosis, 3121 General medicine, internal medicine and other clinical medicine, UMBILICAL-CORD BLOOD, business, LEUKEMIA, Busulfan, 030215 immunology
Abstract

Contains fulltext : 202803.pdf (Publisher’s version ) (Open Access) This analysis included 56 myelofibrosis (MF) patients transplanted from family mismatched donor between 2009 and 2015 enrolled in the European Society for Blood and Marrow Transplantation database. The median age was 57years (range, 38 to 72); 75% had primary MF and 25% had secondary MF. JAK2 V617F was mutated in 61%. Donors were HLA mismatched at 2 or more loci. Stem cells were sourced from bone marrow in 66% and peripheral blood in 34%. The median CD34(+) cell dose was 4.8x10(6)/kg (range, 1.7 to 22.9; n=43). Conditioning was predominantly myeloablative in 70% and reduced intensity in the remainder. Regimens were heterogeneous with thiotepa, busulfan, fludarabine, and post-transplant cyclophosphamide used in 59%. The incidence of neutrophil engraftment by 28days was 82% (range, 70% to 93%), at a median of 21days (range, 19 to 23). At 2years the cumulative incidence of primary graft failure was 9% (95% CI 1% to 16%) and secondary graft failure was 13% (95% CI 4% to 22%). The cumulative incidence of acute graft-versus-host disease (GVHD) grades II to IV and III to IV was 28% (95% CI 16% to 40%) and 9% (95% CI 2% to 17%) at 100days. The cumulative incidence of chronic GVHD at 1 year was 45% (95% CI 32% to 58%), but the cumulative incidence of death without chronic GVHD by 1 year was 20% (95% CI 10% to 31%). With a median follow-up of 32 months, the 1- and 2-year overall survival was 61% (95% CI 48% to 74%) and 56% (95% CI 41% to 70%), respectively. The 1- and 2- year progression-free survival was 58% (95% CI 45% to 71%) and 43% (95% CI 28% to 58%), respectively, with a 2-year cumulative incidence of relapse of 19% (95% CI 7% to 31%). The 2-year nonrelapse mortality was 38% (95% CI 24% to 51%). This retrospective study of MF allo-SCT using family mismatched donors demonstrated feasibility of the approach, timely neutrophil engraftment in over 80% of cases, and acceptable overall and progression-free survival rates with relapse rates not dissimilar to the unrelated donor setting. However, strategies to minimize the risk of graft failure and the relatively high nonrelapse mortality need to be used, ideally in a multicenter prospective fashion.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results